|
Treatment variables by treatment cohort |
||||||||||
| Parameter [statistic] |
All patients |
Olanzapine vs. non-olanzapine |
Risperidone vs. non-risperidone |
Haloperidol vs. non-haloperidol |
||||||
|
|
|
|
|
|||||||
| OLZ |
Non-OLZ |
RIS |
Non-RIS |
HAL |
Non-HAL |
|||||
| (N = 558) |
(N = 390) |
(N = 168) |
p-value |
(N = 72) |
(N = 486) |
p-value |
(N = 132) |
(N = 426) |
p-value |
|
|
|
||||||||||
| Previous pharmacological treatmenta |
||||||||||
| Any previous medication n (%) |
291 (52.2) |
191 (49.0) |
100 (59.5) |
0.022 |
45 (62.5) |
246 (50.6) |
0.060 |
64 (48.5) |
227 (53.3) |
0.335 |
| Any antipsychotic n (%) |
214 (38.4) |
130 (33.3) |
84 (50.0) |
< .001 |
38 (52.8) |
176 (36.2) |
0.007 |
52 (39.4) |
162 (38.0) |
0.778 |
| Olanzapine, n (%) |
52 (9.3) |
48 (12.3) |
4 (2.4) |
5 (6.9) |
47 (9.7) |
13 (9.8) |
39 (9.2) |
|||
| Risperidone, n (%) |
50 (9.0) |
26 (6.7) |
24 (14.3) |
30 (41.7) |
20 (4.1) |
11 (8.3) |
39 (9.2) |
|||
| Haloperidol, n (%) |
45 (8.1) |
30 (7.7) |
15 (8.9) |
5 (6.9) |
40 (8.2) |
25 (18.9) |
20 (4.7) |
|||
| Quetiapine, n (%) |
19 (3.4) |
6 (1.5) |
13 (7.7) |
0 (0.0) |
19 (3.9) |
4 (3.0) |
15 (3.5) |
|||
| Any benzodiazepine n (%) |
106 (19.0) |
75 (19.2) |
31 (18.5) |
0.830 |
10 (13.9) |
96 (19.8) |
0.236 |
22 (16.7) |
84 (19.7) |
0.435 |
| Lorazepam, n (%) |
51 (9.1) |
36 (9.2) |
15 (8.9) |
6 (8.3) |
45 (9.3) |
14 (10.6) |
37 (8.7) |
|||
| Diazepam, n (%) |
43 (7.7) |
29 (7.4) |
14 (8.3) |
3 (4.2) |
40 (8.2) |
7 (5.3) |
36 (8.5) |
|||
| Mood stabilizer n (%) |
67 (12.0) |
48 (12.3) |
19 (11.3) |
0.939 |
7 (9.7) |
60 (12.3) |
0.568 |
11 (8.3) |
56 (13.1) |
0.141 |
| Antidepressants n (%) |
64 (11.5) |
47 (12.1) |
17 (10.1) |
0.679 |
8 (11.1) |
56 (11.5) |
0.976 |
9 (6.8) |
55 (12.9) |
0.056 |
|
|
||||||||||
| Antipsychotic monotherapy n (%) |
227 (40.7) |
183 (46.9) |
44 (26.2) |
< .001 |
13 (18.1) |
214 (44.0) |
< .001 |
11 (8.3) |
216 (50.7) |
< .001 |
| Concomitant benzodiazepine use |
||||||||||
| Any benzodiazepine use n (%) [95% CI (%)] |
389 (69.7) [65.7–73.5] |
268 (68.7) [63.9–73.3] |
121 (72.0) [64.6–78.7] |
0.436 |
52 (72.2) [60.4–82.1] |
337 (69.3) [65.0–73.4] |
0.620 |
110 (83.3) [75.9–89.3] |
279 (65.5) [60.8–70.0] |
< .001 |
| Lorazepam, n (%) |
248 (44.4) |
177 (45.4) |
71 (42.3) |
35 (48.6) |
213 (43.8) |
65 (49.2) |
183 (43.0) |
|||
| Diazepam, n (%) |
175 (31.4) |
109 (27.9) |
66 (39.3) |
29 (40.3) |
146 (30.0) |
75 (56.8) |
100 (23.5) |
|||
| Other, n (%) |
64 (11.5) |
38 (9.7) |
26 (15.5) |
12 (16.7) |
52 (10.7) |
12 (9.1) |
52 (12.2) |
|||
| Benzodiazepine doseb mean (SD), mg |
81.3 (58.1) |
77.9 (52.5) |
89.0 (68.5) |
0.081 |
86.4 (72.5) |
80.6 (55.6) |
0.497 |
76.4 (50.6) |
83.3 (60.8) |
0.296 |
|
a Patients may have received more than one previous pharmacological medication. b Cumulative dose over the complete study period in mg diazepam equivalents. Abbreviations: OLZ = olanzapine, RIS = risperidone, HAL = haloperidol. | ||||||||||
Wilhelm et al. BMC Psychiatry 2008 8:61 doi:10.1186/1471-244X-8-61 |
||||||||||